Rhumbline Advisers Cuts Holdings in Artivion, Inc. (NYSE:AORT)

Rhumbline Advisers trimmed its holdings in shares of Artivion, Inc. (NYSE:AORT) by 1.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 107,320 shares of the company’s stock after selling 1,329 shares during the period. Rhumbline Advisers owned approximately 0.26% of Artivion worth $2,638,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in AORT. Franklin Resources Inc. boosted its stake in shares of Artivion by 2.8% in the 4th quarter. Franklin Resources Inc. now owns 21,707 shares of the company’s stock worth $621,000 after buying an additional 600 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Artivion by 3.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,559 shares of the company’s stock worth $645,000 after buying an additional 727 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after buying an additional 786 shares during the last quarter. Barclays PLC boosted its stake in shares of Artivion by 1.2% in the 4th quarter. Barclays PLC now owns 71,697 shares of the company’s stock worth $2,051,000 after buying an additional 820 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its stake in shares of Artivion by 2.5% in the 4th quarter. New York State Common Retirement Fund now owns 41,017 shares of the company’s stock worth $1,173,000 after buying an additional 1,000 shares during the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 10,548 shares of the firm’s stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $29.13, for a total transaction of $307,263.24. Following the sale, the senior vice president now directly owns 105,332 shares of the company’s stock, valued at $3,068,321.16. This trade represents a 9.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jean F. Holloway sold 9,926 shares of Artivion stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $29.00, for a total value of $287,854.00. Following the completion of the sale, the senior vice president now directly owns 187,258 shares in the company, valued at $5,430,482. This trade represents a 5.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 31,822 shares of company stock valued at $922,831 over the last ninety days. 7.60% of the stock is currently owned by company insiders.

Artivion Price Performance

NYSE:AORT opened at $28.21 on Monday. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The business’s 50-day simple moving average is $26.58 and its two-hundred day simple moving average is $27.45. The stock has a market cap of $1.20 billion, a PE ratio of -1,410.50 and a beta of 1.62. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $32.33.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.06). The business had revenue of $98.98 million for the quarter, compared to the consensus estimate of $94.81 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. As a group, analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analyst Ratings Changes

AORT has been the topic of several analyst reports. Citizens Jmp upgraded Artivion to a “strong-buy” rating in a research report on Tuesday, May 6th. Needham & Company LLC reiterated a “buy” rating and set a $32.00 target price on shares of Artivion in a research report on Tuesday, May 6th. Stifel Nicolaus lowered their target price on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Finally, JMP Securities reiterated a “market outperform” rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday, May 6th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.